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Abstract
Background
The human malaria parasite Plasmodium vivax infects red blood cells through a key path-
way that requires interaction between Duffy binding protein II (DBPII) and its receptor on
reticulocytes, the Duffy antigen/receptor for chemokines (DARC). A high proportion of P.
vivax-exposed individuals fail to develop antibodies that inhibit DBPII-DARC interaction,
and genetic factors that modulate this humoral immune response are poorly characterized.
Here, we investigate if DBPII responsiveness could be HLA class II-linked.
Methodology/Principal Findings
A community-based open cohort study was carried out in an agricultural settlement of the
Brazilian Amazon, in which 336 unrelated volunteers were genotyped for HLA class II
(DRB1, DQA1 and DQB1 loci), and their DBPII immune responses were monitored over
time (baseline, 6 and 12 months) by conventional serology (DBPII IgG ELISA-detected) and
functional assays (inhibition of DBPII–erythrocyte binding). The results demonstrated an
increased susceptibility of the DRB1*13:01 carriers to develop and sustain an anti-DBPII
IgG response, while individuals with the haplotype DRB1*14:02-DQA1*05:03-DQB1*03:01
were persistent non-responders. HLA class II gene polymorphisms also influenced the func-
tional properties of DBPII antibodies (BIAbs, binding inhibitory antibodies), with three alleles
(DRB1*07:01, DQA1*02:01 and DQB1*02:02) comprising a single haplotype linked with
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the presence and persistence of the BIAbs response. Modelling the structural effects of the
HLA-DRB1 variants revealed a number of differences in the peptide-binding groove, which
is likely to lead to altered antigen binding and presentation profiles, and hence may explain
the differences in subject responses.
Conclusions/Significance
The current study confirms the heritability of the DBPII antibody response, with genetic vari-
ation in HLA class II genes influencing both the development and persistence of IgG anti-
body responses. Cellular studies to increase knowledge of the binding affinities of DBPII
peptides for class II molecules linked with good or poor antibody responses might lead to
the development of strategies for controlling the type of helper T cells activated in response
to DBPII.
Author Summary
Vaccines are a crucial component of the current efforts to eliminate malaria, and much of
the vaccine-related research on P. vivax has been focused on the Duffy binding protein II
(DBPII), a ligand for human blood stage infection. A high proportion of individuals who
are naturally exposed to P. vivax fail to develop neutralizing antibodies, but the host
genetic factors modulating this immune response are poorly characterized. We investi-
gated whether DBPII responsiveness was dependent on the variability of human leucocyte
antigen (HLA) class II cell surface proteins involved in the regulation of immune
responses. To obtain a reliable estimate of DBPII antibodies, we carried out a longitudinal
study, collecting serum from the same individuals over a period of 12-months. The results
confirmed the heritability of the DBPII immune response, with genetic variation in HLA
class II genes influencing both the development and persistence of the antibody response.
HLA class II genotype also influenced the ability of DBPII antibodies to block the ligand-
receptor interaction in vitro. Computational approaches identified structural specificity
between HLA variants, which we propose as an explanation for differences between a
good or poor antibody responder. These results may have implications for vaccine devel-
opment, and might lead to strategies for controlling the type of immune response acti-
vated in response to DBPII.
Introduction
Plasmodium vivax infects human reticulocytes through a major pathway that requires interac-
tion between an apical parasite protein, the Duffy binding protein (DBP), and its cognate recep-
tor on reticulocytes, the Duffy antigen/receptor for chemokines (DARC) [1–3]. Although most
individuals lacking DARC on their red blood cells (RBCs) are naturally resistant to P. vivax [1],
some infections occur in DARC-negative individuals living in vivax malaria endemic areas [4–
6, 70]. So far, no alternative ligand facilitating the binding of P. vivax to reticulocytes has been
identified, which makes the DBP one of the most promising P. vivax vaccine targets [8].
The importance of the interaction between DBP (region II, DBPII) and DARC to P. vivax
infection has stimulated a significant number of studies on DBP antibody responses (reviewed
in [8]). The available data demonstrate that naturally occurring antibodies to DBP are
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prevalent amongst individuals living in P. vivax endemic areas, and that these antibodies can
inhibit the DBPII-DARC interaction [7, 9–12]. Even though DBPII-specific binding inhibitory
antibodies (DBPII BIAbs) seem to confer a degree of protection against blood stage infection
[11], the majority of people naturally exposed to P. vivax do not develop a DBPII BIAbs
response [8]. In the Amazon Basin, for example, this inhibitory activity was detected in only
one third of malaria-exposed subjects [8, 13]. Similarly, less than 10% of children from Papua
New Guinea (PNG) with immunity to malaria had acquired high levels of DBPII BIAbs [11].
Given the significant differences in epidemiology and parasite genetics between the Amazon
Basin and PNG, the fact that the DBPII BIAbs response is relatively low but also remarkably
stable over time is particularly intriguing.
The reasons for the low immunogenicity of DBPII are not clear, but may be linked to a
complex immune response driven by genetic diversity in both the parasite and human popula-
tions. Several studies have demonstrated the existence of variant specificity in the natural
immune response against DBPII, which has been attributed to allelic diversity [12, 14]. On the
host side, recent evidence suggests that host genetic polymorphisms might also affect humoral
immunity against DBP [15, 16], with DARC polymorphisms thought to affect the ability of
DBP antibodies to block parasite invasion [16]. In a previous study, we demonstrated that the
naturally acquired BIAbs response tended to be more frequent in heterozygous individuals
carrying a DARC-silent allele (FYBES), which suggested that gene-dosage effect occurred [7].
In this context, we were interested in determining if DBPII non-responsiveness could be asso-
ciated with variation in the major histocompatibility complex.
While malaria infection represents a key selection pressure for the human leukocyte antigen
(HLA), and has left clear evolutionary footprints on the alleles observed in different countries
[17], the association between HLA gene expression and responsiveness (or non-responsive-
ness) to defined malaria antigens has produced contradictory results [18–21]. Beyond the
extreme genetic diversity of HLA class II, which hinders interpretation of the role of HLA on
antibody responses elicited during malaria, most studies rely on antibody prevalence data col-
lected at a single time-point in cross-sectional analysis of a population. Since malaria transmis-
sion is intermittent and seasonal in many endemic areas, it is possible that antibody levels
fluctuate over time such that individuals could appear to be non-responders on some occa-
sions and responders on others [20]. In the current study, we present data of the first ongoing
population-based study of the relationship between HLA class II genes and DBPII immune
response. The methodological approach included a community-based open cohort study in an
agricultural settlement of the Brazilian Amazon, in which 336 unrelated volunteers were geno-
typed for HLA class II (DRB1, DQA1 and DQB1 loci), and their DBP immune responses were
monitored over time by conventional serology (DBPII IgG ELISA-detected) and functional
assays (DBPII BIAbs).
Methods
Study area and population
The study was carried out in the agricultural settlement of Rio Pardo (1˚46’S—1˚54’S, 60˚
22’W—60˚10’W), in the Presidente Figueiredo municipality, located in the Northeast of Ama-
zonas State in the Brazilian Amazon. The Rio Pardo settlement is located approximately 160
km from Manaus, the capital of Amazonas, along the main access to a paved road (BR-174)
that connects Amazonas to Roraima (Fig 1). The settlement was officially created in 1996 by
the National Institute of Colonization and Agrarian Reform (INCRA) as part of a large-scale
colonization project focused on agriculture and wide-ranging human settlement in the Ama-
zon area [22]. The mean annual temperature is 31˚C with a humid climate and an average
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annual rainfall of 2,000 mm per year. The rainy season extends from November to May, and
the dry season from June to October. According to a census conducted between September
and October 2008, Rio Pardo has 701 inhabitants, most of whom live on subsistence farming
and fishing along the tributaries of the Rio Pardo River. The study population was quite stable.
Most residents were native to the Amazon region, and their average age of 28 years roughly
corresponded to the time of malaria exposure in the Amazon area [7]. In the study area, migra-
tion rates were relatively low, as only 28 (8%) of 336 individuals moved out of the village dur-
ing the follow-up period.
Based on the spleen size of the local children and parasite infection rates, the study area was
classified as hypo- to mesoendemic, which is consistent with the general profile of malaria
infection for well-established frontier settlements in the Amazon region [23]. The study site
and malaria transmission patterns have been described in detail elsewhere [7]. Although P.
vivax and P. falciparum are transmitted year round, P. vivax is responsible for about 90% of
malaria cases in the region. Similar to other parts of the Brazilian Amazon area [24], a continu-
ous decrease in the number of malaria cases has been reported in the Rio Pardo community;
in 2008, the local Annual Parasitological Index (API) was 131 cases per 1000 inhabitants, while
in 2009 the API was 54.6 (Health Surveillance Secretariat of the Brazilian Ministry of Health,
SVS/MS). In the study area, precarious living conditions, including houses with partial walls
and roofs made of tree leaves, increase human-vector contact and reduce indoor residual
spraying efficacy [23]. However, while the availability of curative services is limited, a govern-
ment outpost in the area provides free malaria diagnosis and treatment.
Study design and cross-sectional surveys
The ethical and methodological aspects of this study were approved by the Ethical Committee
of Research on Human Beings from the Centro de Pesquisas Rene´ Rachou (Reports No.
Fig 1. Map of the state of Amazonas, Northwestern Brazil, showing the study site. The Rio Pardo
settlement is located within the Presidente Figueiredo municipality (grey area in the inset), roughly 160 km
from the state capital, Manaus.
doi:10.1371/journal.pntd.0005177.g001
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007/2006, No. 07/2009, No. 12/2010 and No. 26/2013), according to the Resolution of the Bra-
zilian Council on Health-CNS 466/12. In November of 2008, 541 of the 701 residents of the
settlement (77.2%) invited to participate in the study accepted by giving written informed con-
sent, which was also obtained from the next of kin, caregivers, or guardians on the behalf of
participating minors.
A population-based open cohort study was initiated in November of 2008, with the follow-
ing procedures: (i) administration of a structured questionnaire to all volunteers to obtain
demographical, epidemiological, and clinical data; (ii) physical examination, including body
temperature and spleen/liver size, recorded according to standard clinical protocols; (iii)
venous blood collection for individuals aged five years or older (EDTA, 5 mL), or blood spot-
ted on filter paper (finger-prick) for those aged <5 years; and (iv) examination of Giemsa
thick blood smears for the presence of malaria parasites via light microscopy. The geographical
location of each dwelling was recorded using a hand-held 12-channel global positioning sys-
tem (GPS) (Garmin 12XL, Olathe, KS, USA) with a positional accuracy of within 15 m. At the
time of initial enrollment in the study, 222 out of 541 volunteers had no familial relationships
with other volunteers, and were consequently selected for HLA genotype and serological
assays.
Six and twelve months after the initial survey, two similar cross-sectional surveys were car-
ried out. In total, 336 unrelated subjects were enrolled in the study, with 222 examined in the
baseline cohort, 249 examined during the 2nd survey (June, 2009), and 239 during the 3rd sur-
vey (October-November, 2009). A total of 244 (72.6%) subjects had consecutive samples taken,
and 156 of these (64%) had samples taken in all cross-sectional surveys (baseline, 6 and 12
month follow-up).
Laboratory diagnosis of malaria
Malaria infections were diagnosed by microscopy of Giemsa-stained thick blood smears, and
by Real-Time PCR amplification of a species-specific segment of the multicopy 18SSU rRNA
gene of human malaria parasites. The Giemsa-stained smears were evaluated by experienced
microscopists, according to the malaria diagnosis guidelines of the Brazilian Ministry of
Health. For Real-Time PCR, genomic DNA was extracted from either whole blood samples
collected in EDTA, or from dried blood spots on filter paper using the Puregene blood core kit
B (Qiagen, Minneapolis, MN, USA) or the QIAmp DNA mini kit (Qiagen), respectively,
according to manufacturers’ instructions. Real-Time PCR was performed as previously
described [25].
HLA genotyping
Molecular amplification of the alleles of HLA-DRB1, HLA-DQB1 and HLA-DQA1 were per-
formed by the PCR-SSO (polymerase chain reaction, specific sequence of oligonucleotides)
technique, with Luminex technology (One Lambda Inc., Canoga Park, CA, USA). Briefly, tar-
get DNA was PCR-amplified using group-specific primer sets, after the amplified product was
biotinylated, which allowed later detection using R-Phycoerythrin-conjugated Streptavidin
(SAPE), and hybridized with microspheres linked to specific conjugated fluorescent probes for
each HLA allele group (One Lambda, Canoga Park, CA, USA). The fluorescent intensity varied
based on the reaction outcome, with an expected intensity of 1000 or more for positive control
probes. Reaction readings were carried out by flow cytometry using Luminex technology (One
Lambda). Samples were analyzed through the HLA FUSION software (One Lambda Inc., San
Diego, CA, USA).
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Recombinant DBPII and ELISA-detected IgG antibodies
A conventional enzyme-linked immunosorbent assay (ELISA) for total IgG antibodies to
DBPII was carried out using a recombinant protein that included amino acids 243–573 (region
II) of the Sal-1 DBPII variant, which is highly prevalent in the study area [23]; the recombinant
protein was expressed as a 39 kDa 6xHis fusion protein, as previously described [26]. ELISA
was carried out as previously described [27], with serum samples at 1:100 and DBPII at a final
concentration of 3 μg/ml. The results were expressed as reactivity index (RI), calculated by
dividing the reading values of the test (OD values) by the cut-off (mean reading for the unex-
posed group plus 3 SD, n = 30). Values of RI> 1.0 were considered positive.
COS7 cells transfections and DBPII inhibitory binding assays
COS7 cells (green monkey kidney epithelium, ATCC, Manassas, VA) were transfected with
the plasmid pEGFP-DBPII, which coded for a common DBPII sequence circulating in the
Amazon area [13]. Transfections were performed with lipofectamine and PLUS-reagent (Invi-
trogen Life Technologies, Carlsbad, CA) according to manufacturer’s protocols. Forty-eight
hours post-transfection, erythrocyte-binding assays were performed as previously described
[10]. Briefly, plasma samples were added at 1:40, and plates were incubated for 1 hr at 37˚C in
5% CO2. Human O+ DARC+ erythrocytes in a 10% suspension were added to each well
(200 μl/well), and plates were incubated for 2 h at room temperature. After incubation,
unbound erythrocytes were removed by washing the wells three times with phosphate buffered
saline (PBS). Binding was quantified by counting rosettes observed in 10–20 fields of view
(x200). Positive rosettes were defined as adherent erythrocytes covering more than 50% of the
COS cell surface. For each assay, pooled plasma samples from Rio Pardo residents character-
ized as non-responders by ELISA were used as a negative control (100% binding). For this pur-
pose, only plasma that did not inhibit erythrocyte binding was pooled for use as the negative
control (usually, 10 plasma samples/pool). The positive control included a pool of plasma from
individuals with long-term exposure to malaria in the Amazon area. The percent inhibition
was calculated as 100 x (Rc—Rt)/Rc, where Rc is the average number of rosettes in the control
wells, and Rt is the average number of rosettes in the test wells. Plasma samples with more
than 50% of binding inhibition were considered positive.
Prediction of DBPII—HLA class II binding affinity
To predict HLA-DR/-DQ binding affinities (IC50) we used the P. vivax DBP sequence
(XP_001608387.1) from the NCBI database. Each potential 15-mer sequence frame was scored
using the NetMHCIIpan-3.1 server (http://www.cbs.dtu.dk/services/NetMHCIIpan-3.1/), an
improved version of the tool that permits a much more accurate binding core identification
[28]. Binding affinity was given as the log IC50 value in nanomolar (nM), and the defined
thresholds for strong and weak binders were<1.7 nM and<2.7 nM, respectively.
Modelling the structural effects of the HLA class II variants
Homology models of the three DRB1 variants were generated using Modeller and Macro
Model (Schrodinger, New York, NY) using an ensemble of previously solved X-ray crystal
structures of the HLA II beta chain (PDB IDS: 1IEB Chain D, 3LQZ Chain B and 1SEB Chain
B; 76%, 67% and 90% sequence identity respectively). The alpha chain was modelled using an
ensemble of available X-ray crystal structures including PDB IDs: 2Q6W and 4AEN (Chain D
and A respectively, 100% sequence identity). As previously described [29, 30], the models were
then minimized using the MMF94s forcefield in Sybyl-X 2.1.1 (Certara L.P., St Louis, MO),
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with the final structure having more than 95% of residues in the allowed region of a Rama-
chandran plot. The quality of the models was confirmed with Verify3D. The models of the
HLA II complex of the alpha and beta chains were built using X-ray crystal structures of the
complex (PDB ID: 1IEB, 3LQZ, 1SEB, 2Q6W, 4AEN) to guide protein docking [31]. Two rep-
resentative DBPII antigenic peptides (H1: FHRDITFRKLYLKRKL; H3: DEKAQQRRKQWW-
NESK) were modelled into each HLA II complex variant using the available crystal structures
of the HLA II complexes to guide docking. Binding affinities were predicted using CSM-lig
[32]. Model structures were examined using Pymol.
The structural consequences of each amino acid difference between the DRB1 variants
were analyzed to account for all the potential effects of the mutations [33]. The effects of the
variations on the stability of DRB1 and the HLA II complex were predicted using DUET [34],
an integrated computational approach that optimizes the prediction of two complementary
methods (mCSM-Stability and SDM). The effect of the differences on the protein-protein
binding affinity between the alpha and beta chains to form the HLA II complex were predicted
using mCSM-PPI [35]. The effect of the changes on the binding affinity of the HLA II complex
for a model peptide were also analysed using mCSM-PPI, as previously described [36],
mCSM-lig [37], and mCSM-AB [38]. These computational approaches represent the wild-type
residues structural and chemical environment of a residue as a graph-based signature in order
to quantitatively determine the change upon mutation in Gibb’s Free Energy of stability or
binding.
Statistical analysis
A database was created using Epidata software (http://www.epidata.dk). Linear correlation
between two variables was determined by using the Spearman’s correlation coefficient. Differ-
ences in proportions were evaluated by chi-square (Χ2) test and, differences in medians were
tested using either the Mann-Whitney or Kruskal–Wallis tests, with Dunn’s post hoc test, as
appropriate. For allelic group comparison, differences in proportion were performed by Z-test
or chi-square tests, or Fisher’s exact tests, as appropriate. Alleles frequencies for each locus
(DRB1, DQA1, and DQB1) were summarized descriptively using frequencies and percentage
for immunological categorical variables.
Overall associations with immunological responses and alleles from each locus of HLA
class II were evaluated by comparing the allele frequencies between seronegative individuals
and seropositive individuals from the baseline study using standard contingency tables. Based
on the humoral immune response to DBPII from the three cross-sectional surveys, the long-
term immune responses against DBPII were grouped into three categories: (i) Persistent non-
responder (PNR)—absence of antibodies against DBPII in all three cross-sectional surveys; (ii)
transient responder (TR)—antibodies detected in at least one cross-sectional survey; (iii) Persis-
tent responder (PR)—individuals with detectable DBPII antibodies in all three cross-sectional
studies. The association between HLA class II alleles (or haplotypes) and long-term immune
response (PR or PNR groups) was analyzed by standard contingency tables (Chi-square and
Fisher’s exact test, as appropriate), with two observations per subject (one for each allele).
Alleles with a frequency of less than 0.01 were not included in the analysis.
Additionally, multiple logistic regression models with stepwise backward deletion were
built to describe independent associations between covariates and HLA class II alleles or hap-
lotypes and antibodies to DBPII. Covariates were selected for inclusion in the logistic models if
they were associated with the outcome at the 15% level of significance in exploratory unad-
justed analysis. Logistic regression models included the following covariates: age, gender,
exposure to malaria (time of residence in the endemic area), self-reported malaria episodes,
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recent malaria infection and household location within the study area. Multivariate logistic
regression was performed using Stata software version 10 (Stata Corporation, College Station,
TX). Only variables associated with statistical significance at the 5% level were maintained in
the final models. To avoid type II errors due to overly severe correction, statistical adjustment
for multiple tests were not used [39, 40]. Type I errors were reduced by using multiple logistic
regression models with stepwise backward deletion. Estimated genotype distribution between
the observed and expected allelic frequencies was tested using the method described by Guo
and Thompson [41] to verify Hardy-Weinberg equilibrium. Because the gametic phase was
unknown, maximum-likelihood estimates of haplotype frequencies were obtained from multi-
locus genotype data and computed using the expectation-maximization (EM) algorithm [42].
Both procedures were performed using Arlequin software version 3.5 (http://cmpg.unibe.ch/
software/arlequin35/) [43].
Results
Malaria infection and DBPII-specific antibodies at enrollment
We evaluated DBPII antibody responses in 336 unrelated subjects with a median of age 41
years and a 1.3:1 male-female ratio (Table 1). Age was significantly associated with a subject’s
time of malaria exposure in the Amazon area (r = 0.82; p<0.0001, Spearman’s correlation
test). At the time of the first blood collection, the overall prevalence of malaria was 5%, with 14
out of the 17 (82%) infections caused by P. vivax and 3 (18%) by P. falciparum. No P. malariae
or mixed Plasmodium infections were diagnosed by either microscopy or Real-Time PCR. The
336 participants were followed up for an average of 7.5 months (10 days to 12 months), thus
representing 2,514 person-months of follow-up. Based on parasitological-confirmed cases, the
incidence rates of P. vivax malaria were 1.03 episodes per 100 person-months (95% confidence
Table 1. Demographical, epidemiological and immunological data of the study population, 336 unre-
lated inhabitants of the agricultural settlement of Rio Pardo, Amazonas, Brazil.
Characteristic
Age, median, years (IQR) a 41 (25–51)
Gender ratio, male:female 1.3:1
Years of malaria exposure, median (IQR)b 33 (21–48)
Years of residence in Rio Pardo, median (IQR) c 7.5 (4–12)
Previous malaria episodes, median (IQR) 5 (1–11)
Acute malaria infection, n (%) d 17 (5.0)
P. vivax 14 (4.1)
P. falciparum 3 (0.9)
DBPII antibody response, positive (%) e 122 (36)
DBPII binding inhibitory antibodies [n = 164], positive (%)f 58 (35.4)
a IQR = interquartile range
b Time living in the endemic area (Brazilian Amazon)
c Time living in the agricultural settlement area
d Malaria infection was detected by conventional light microscopy and/or real-time PCR at the time of their
first blood-collection (individual baseline); no mixed infections were found in this study
e ELISA-detected IgG antibodies targeting DBPII; results are expressed as the number (%) of individuals
with a positive antibody response at the time of their first blood-collection
f Functional assays with transfected COS cells to detect DBPII binding inhibitory antibodies (BIAbs) were
performed on a subpopulation of the study sample
doi:10.1371/journal.pntd.0005177.t001
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interval [CI] of 0.69–1.49/100 person-months) and 0.19 per 100 person-months for P. falcipa-
rum (95% CI of 0.03–0.32/100 person-month).
One hundred and twenty-two (36%) of the individuals enrolled in the study had ELISA-
detected IgG antibodies to the main variant of DBPII circulating in the study area (Sal-1)
(Table 1). Because not all DBPII IgG antibodies are able to block the interaction between the
ligand (DBPII) and its receptor on the RBC surface (DARC), we evaluated the functional prop-
erties of the anti-DBPII antibodies. Due to the methodological constraints of performing func-
tional assays, measurement of DBPII binding inhibitory antibodies (BIAbs) was performed on
a representative subset of the study population comprising 164 individuals, matched for age,
sex, malaria exposure and DARC alleles; 58 (35.4%) of these individuals showed BIAbs
response against a predominant DBPII variant circulating in the study area (Table 1).
Evaluation of long-term natural DBPII-specific IgG antibodies
Since the number of malaria cases varied during the course of the study (Fig 2A), we evaluated
the long-term antibody response at different levels of malaria transmission. Over three cross-
sectional surveys, at 6-month intervals, between 38 to 40% of individuals developed DBPII IgG
antibodies, as detected by conventional serology (Fig 2B). Considering the inhibitory antibody
response, there was a slight decrease in the frequency of BIAbs at the time of the 3rd cross-sec-
tional survey (34–35% to 25%) (Fig 2C). Finally, the 12-month follow-up study allowed indi-
viduals to be classified as persistent non-responders (PNR), transient responders (TR), or
persistent responders (PR) for either conventional serology or BIAbs immune response (Fig
2D). For conventional and inhibitory antibody responses, the frequency of acute malaria infec-
tions was similar between the PNR, TR or PR groups (p>0.05 for all comparisons).
Distribution of HLA class II in the study population and association with
ELISA-detected DBPII IgG antibodies
Of the HLA class II loci that were genotyped in the study population, we found 13 HLA-DRB1,
6 HLA-DQA1, and 5 HLA-DQB1 allele groups. As expected, HLA-DRB1 was the most poly-
morphic locus with 46 alleles identified; there were 21 and 13 DQB1 and DQA1 alleles, respec-
tively. For each HLA class II locus, the predominant alleles (frequency 0.01) were listed in
the S1 Fig.
In a preliminary analysis, the effect of HLA class II genes on conventional DBPII antibody
response was evaluated at the time of the first blood collection (S1 Table). While three HLA
class II alleles (DRB113:01, DQA101:03, DQB106:03) were positively associated with anti-
DBPII antibody response, six alleles (DRB110:01, DRB114:02, DQA101:01, DQA105:03,
DQB103:01, DQB105:01) were negatively associated. Nevertheless, using multiple logistic
regression models, only the DRB113:01 (presence) and DRB114:02 (absence) alleles were sig-
nificant predictors of anti-DBPII antibodies (Fig 3A).
Since combinations of HLA alleles are inherited together in the genome more often than
expected, we further evaluated the association between ELISA-detected DBPII-specific anti-
bodies and HLA class II haplotypes. In total, 126 combinations of specific DRB1, DQA1, DQB1
haplotypes were found, and for 27 of them (frequency 0.01) it was possible to estimate the
individual probability of developing DBPII antibodies. Adjusted logistic regression analysis
identified a single haplotype associated with poor production of DBPII antibodies, with indi-
viduals carrying the haplotype DRB114:02-DQA105:03-DQB103:01 5-times less likely to
develop a conventional DBPII antibody response (Fig 3A). In addition, for each HLA class II
locus analyzed (DRB1, DQA1, and DQB1), the genotype frequencies were confirmed to be in
Hardy-Weinberg equilibrium (for the responder vs. non-responder groups).
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Fig 2. Temporal distribution of P. vivax malaria episodes and immune response targeting region II of the
Duffy binding protein (DBPII), Rio Pardo Settlement, Amazonas, Brazil (Nov. 2008 –Nov. 2009). (A) Monthly
malaria notifications in the Rio Pardo settlement (SVS/MS, Surveillance Service database, Brazilian Ministry of
Health). Episodes of malaria, as determined by conventional microscopy, varied according to rainfall and season.
Arrows indicate the time of the cross-sectional surveys (November, 2008; June 2009; and November, 2009). (B)
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Next, we investigated whether the status of persistent responder (PR) or non-responder
(PNR) was HLA class II-linked at the time of the 12-month follow-up collection. The frequen-
cies of some HLA class II alleles were significantly different between the PR and PNR groups
(S2 Table). An adjusted odds ratio analysis confirmed that two alleles were associated with the
status of long-term responder, and a single allele was associated with the absence of an anti-
body response (Fig 3B). More specifically, while individuals carrying either the DRB113:01 or
DQA101:03 alleles had an increased probability of a sustained antibody response, the
DQA105:03 allele carriers were associated with the status of persistent non-responders (Fig
3B). It is noteworthy that the DQA105:03 allele aggregated in a specific haplotype
(DRB114:02-DQA105:03-DQB103:01) that was primarily associated with the absence of an
antibody response (Fig 3A), and this haplotype was in strong linkage disequilibrium (Δ = 1.0;
P = 0).
HLA class II variability and DBPII inhibitory immune response
Further experiments investigated whether HLA class II polymorphisms interfered with the
functional proprieties of DBPII antibodies. The three cross-sectional measures of DBPII
DBPII IgG ELISA-detected antibody (Anti-DBPII) response remained stable during the follow up period (Baseline,
and at 6 or 12 months). Results are expressed as a frequency (%) of responders, and a Reactivity Index (RI) of
greater than 1.0 was considered positive. (C) DBPII binding inhibitory antibodies (BIAbs) had a slightly decreased
frequency at the 12 months follow-up examination. BIAbs were evaluated by COS-7 cytoadherence assay, using
plasma samples diluted to 1:40 (n = 164). Positive results were considered as DBPII–DARC binding inhibition of
50%. (D) Based on conventional (ELISA-detected IgG) and functional serology assays (DBPII BIAbs) at 12 months
of follow-up, individuals were classified as persistent non-responder (PNR)—no antibody response detected any
time-point of the follow-up; transient responder (TR)—antibodies detected in at least one cross-sectional survey; or
persistent responder (PR)–antibodies detected in all cross-sectional surveys.
doi:10.1371/journal.pntd.0005177.g002
Fig 3. Association between HLA class II alleles (DRB1, DQA1, and DQB1 loci) and Plasmodium vivax Duffy binding protein (DBPII)
antibody responses in individuals naturally exposed to malaria. (A) At enrollment (baseline), adjusted Odds Ratio (aOR) analysis for
the association of HLA class II (alleles and haplotypes) and the presence (black circle) or absence (white circle) of DBPII IgG antibody (Ab)
response, as detected by ELISA. (B) After 12-month follow-up, adjusted Odds Ratio (aOR) analysis for the association of HLA class II
(alleles and haplotypes) and the long-term DBPII antibody response; individuals were classified as persistent non-responder (PNR, white
square) or responder (PR, black square), as described in legend of Fig 2. Adjusted ORs analyses were performed using multivariable
logistic regression models adjusted for confounding variables (age, sex, previous malaria episodes, and dwelling location). Variables
associated with DBPII antibody at 5% level (p < 0.05) were maintained in the final models.
doi:10.1371/journal.pntd.0005177.g003
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BIAbs responses were performed on a subset of the study population comprising 164 indi-
viduals (Table 1), with responders (n = 58) and non-responders (n = 106) matched for age,
sex, and malaria exposure. Three alleles (DRB107:01, DQA102:01, and DQB102:02) were
overrepresented in DBPII BIAbs responders (S3 Table), and these same alleles aggregated in
a haplotype (Fig 4A), which was in linkage disequilibrium (Δ = 0.90 and 0.94, for responders
and non-responders, respectively). Interestingly, the long-term persistence of anti-DBPII
responses (determined at the 12 month follow-up analysis) was also associated with those
same three HLA class II alleles (Fig 4B). Unfortunately, the small size of the sample pre-
cluded use of adjusted odds ratio analyses. Nonetheless, responder and non-responder
groups were matched by the confounding variables (age, sex, malaria exposure, and dwelling
localization).
In silico binding prediction of DBPII peptides to class II allelic variants
Since persistence and functional properties of DBPII antibodies were influenced by class II
allelic variants, we investigated whether differences in the affinity of DBPII peptides for
class II molecules might contribute to the observed difference in responses. Based on pre-
dicted binding affinity between DBPII peptides and HLA-DR/DQ alleles, we found unex-
pected differences in affinity in favor of the non-responder allele carriers. Actually, the
HLA-DR allele linked to non-responders (DRB114:02) appeared to have a higher binding
affinity for the peptides (low IC50 values) than the HLA–DR alleles that were associated
with responders (DRB107:01 and DRB113:01) (S2 Fig). In spite of that, different HLA-DR
binding profiles were found for previously identified DBPII epitopes [44–47]. Of note, the
recently described broadly neutralizing DBPII epitopes (2D10/2H2 and 2C6) had low bind-
ing affinity for all of the Class II molecules analyzed (S2B Fig). Considering HLA-DQ, the
model also showed a higher predicted binding affinity for HLA-DQA1/B1 molecules linked
to non-responders.
Fig 4. Association between HLA class II alleles (DRB1, DQA1, and DQB1 loci) and Plasmodium vivax Duffy binding protein (DBPII)
binding Inhibitory Antibodies (BIAbs) in individuals naturally exposed to malaria. (A) At enrollment (baseline), Odds Ratio (OR)
analyses for the association of HLA class II (alleles and haplotypes) and DBPII BIAbs response, as detected by functional assays with
DBPII- transfected COS cells; black circles represent alleles and haplotypes of HLA class II associated with a positive BIABs response. (B)
After 12-month follow-up, Odds Ratio analyses for the association of HLA class II (alleles and haplotypes) and long-term DBPII BIAbs
response; individuals were classified as persistent non-responder (PNR) or responder (PR, black square), as described in legend of Fig 2.
Odds Ratio analyses realized using standard contingency tables (p < 0.05; qui-square and Fisher’s exact test, as appropriate).
doi:10.1371/journal.pntd.0005177.g004
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Structural analysis of HLA-DRB1 variants
Structural analysis of the three HLA-DRB1 variants revealed a number of interesting differ-
ences in the peptide-binding groove (S3 Fig), with significant alterations to its electrostatic
potential, and reduced affinity for the model peptides (Fig 5A–5C), which we propose as an
explanation for the differences in subject responses. The antigenic surface of DBPII has a
strong positive charge (S4 Fig), which is suggestive of a binding preference for antibodies tar-
geting positively charged epitopes such as those that will be preferentially bound by the
DRB107:01 and DRB113:01 variants. Interestingly, while the DRB114:02 and DRB113:01
variants are the closest in sequence identity, the docked peptides were most similar between
the two responder variants (rmsd of the peptides < 3.8 Å), whilst the non-responder did not
dock in a similar way (rmsd of the peptides > 8 Å). This supports the suggestion that the non-
responder variant leads to reduced antigen presentation.
Overall, while the non-responder-associated variant (DRB114:02) shares 81.2% and 95.5%
sequence identity to DRB107:01 and DRB113:01, respectively, the sequence identity is lower
in the groove region within 5 Å of the presented antigen (DRB107:01–73.3%; DRB113:01–
89.6%). While the majority of the differences between the variants are located within the pep-
tide-binding domain, this change in the nature of the antigen-binding groove is evident in dif-
ferences between their isoelectric points, with DRB107:01 and DRB113:01 having slightly
acidic pI’s (6.5 and 7.0 respectively), and DRB114:02 being basic (7.7). It was also reflected in
the energy calculations, with DRB114:02 having an overall Coulomb energy approximately
1.5% lower than either of the responder variants.
One significant difference between the good and poor responder variants was the presence
of a glutamine residue at position 99 (247 according to the Protein Data Bank, PDB) in
DRB114:02, compared to aspartic acid in DRB107:01 and DRB113:01. This residue side-
Fig 5. The HLA II complex peptide-binding groove. The figure presents a representation of the HLA II
complex electrostatic surface potential, and interactions made by residue 99 of DRB1 for the responder
alleles DRB1*07:01 (A and D, respectively) and DRB1*13:01 (B and E, respectively), and the non-responder
allele DRB1*14:02 (C and F, respectively). The DBPII H1 peptide is shown inside the binding groove as green
sticks. Hydrogen bonds are shown as red dashed lines.
doi:10.1371/journal.pntd.0005177.g005
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chain points into the peptide-binding groove and is located approximately 5 Å from the anti-
gen peptide backbone, making a key hydrogen bond (Fig 5D and 5E). Here, loss of the acidic
residue in the peptide-binding groove was predicted to reduce the H1 and H3 peptide binding
affinity (ΔΔG< -0.8 kCal/mol), and is likely to lead to altered antigen binding and presenta-
tion profiles, and hence the poor response seen for DRB114:02 variant carriers.
Discussion
The HLA molecules encoded by MHC class II genes are responsible for presenting peptide
epitopes to CD4+ T helper cells. Consequently, it is reasonable to postulate that polymor-
phism in the HLA class II region may account for the variation in DBPII antibody responses.
Unfortunately, most antibody prevalence data on malaria have been collected by cross-sec-
tional analysis at a single time point, which might led to misclassification of individual
immune responsiveness. Therefore, in this study we conducted a longitudinal study, collect-
ing serum from the same individuals over a period of 12 months, to obtain a reliable estimate
of DBPII antibody prevalence. The genetic profile of HLA class II in the study population
was similar to other populations of the Brazilian Amazon [48], which are characterized by an
interethnic admixture with high proportions of European and Amerindian groups [49].
Accordingly, in the study population 44% had European ancestry, followed by 38% Amerin-
dian, and 18% African ancestry. For other Brazilian regions, the contribution of European
ancestry has ranged from 40% in the Northeast to >70% in the Southeast and South [50, 51].
As expected, the Native-American ancestry in the study area (38%) was representative of the
Amazonian region, where Amerindian ancestry is much higher that in other Brazilian
regions (<10%) [50].
Our current study confirms the heritability of antibody responses to DBPII, with genetic
variation in HLA class II molecules influencing both the development and persistence of an
individual’s anti-DBPII IgG antibody response. Accordingly, multivariate analyses adjusted
for potential confounding variables showed effects of alleles linked to the DR and DQ loci on
the presence (DRB113:01) and persistence (DRB113:01 and DQA101:03) of ELISA-detected
DBPII IgG antibodies. On the other hand, two alleles were associated with DBPII-non-respon-
siveness, DRB114:02 and DQA105:03, and these comprised a single haplotype
(DRB114:02-DQA105:03-DQB103:01) that significantly reduced the development of anti-
DBPII IgG at any time during the follow-up study (baseline, 6 and 12 months later). Interest-
ingly, the alleles in the aforementioned haplotype were in strong linkage disequilibrium, which
demonstrated that these poor-responder alleles are inherited together more often than
expected by chance. So far, only a single study has investigated the association between HLA
and DBPII antibodies [52]. Although in that case the authors were unable to demonstrate an
association between HLA type and ELISA-detected DBP IgG antibodies, and the relatively lim-
ited number of responders did not allow any final conclusions about the highly polymorphic
HLA class II and DBP antibodies.
Here, the assessment of long-term antibody response was essential to strengthen the con-
clusion that there was an increased susceptibility of DRB113:01 carriers to develop and sustain
their anti-DBPII IgG antibody response. Furthermore, these data confirmed that individuals
harboring the haplotype DRB114:02-DQA105:03-DQB103:01 were persistent non-respond-
ers. Due to the overall scarcity of data combining analysis of HLA and immune responses to P.
vivax, further confirmation of these associations in other malaria endemic areas is needed.
Despite the remarkable lack of data on this subject, systematic review and meta-analysis stud-
ies have identified a link between the DRB113:01 allele and increased antibody responses to
vaccines for other microbial infections, including hepatitis B, influenza virus, serogroup C
Plasmodium vivax Duffy Binding Protein II Antibodies and HLA Class II
PLOS Neglected Tropical Diseases | DOI:10.1371/journal.pntd.0005177 December 13, 2016 14 / 21
meningococcus, and MMR-II (measles and rubella virus) [53, 54]. Additionally, the DRB114
allelic group has been associated with a poor humoral response to HBsAg vaccination [55].
Many field studies examining the immune response to malaria have focused on measuring
the concentrations of antibodies to vaccine candidate antigens, while less attention has been
paid to complementary approaches defining the functional relevance of these antibodies. By
using an in vitro assay to quantify inhibition of DBPII–erythrocyte binding [9, 56], we demon-
strated that DBPII binding inhibitory antibodies (BIABs) were associated with three alleles
(DRB107:01, DQA102:01 and DQB102:02), which are in linkage disequilibrium and were
found to be part of a single haplotype. Notably, these three alleles were associated with the
presence of BIAbs antibodies and were also associated with the persistence of this inhibitory
response. Therefore, our observations may explain previous results showing that the majority
of people who are naturally exposed to P. vivax do not develop antibodies that inhibit the
DBPII-DARC interaction, but once they are acquired these BIAbs seem to be stable under con-
tinuous exposure to malaria transmission [11, 13].
Intriguingly, a significant number of pharmacogenetic studies have identified HLA-
DRB107:01 carriers (in less extension, DQA102:01 and DQB102:02) as being more suscepti-
ble to side effects of biological therapy due to the activation of immune response drug-induced
[57–59]. Notably, part of the side effect could be explained by the higher production of neutral-
izing antibodies against drugs (or their metabolites) in the HLA-DRB107:01 and/or DQA102
carriers [59, 60]. Although drug-specific antibodies are undesirable in therapies involving bio-
logical proteins, these findings reinforce our results of a much higher frequency and persis-
tence of DBPII neutralizing antibodies in individuals harboring those alleles HLA class II. In
future studies, functional analysis of a greater number of individuals might allow for more
robust statistical comparisons.
It is noteworthy that the class II alleles associated with DBPII inhibitory activity were not
associated with the conventional IgG antibody responses. Likewise, alleles (or haplotypes)
associated with ELISA-detected IgG antibodies were not associated with DBPII BIAbs. These
results are not completely unexpected because quantitative receptor binding assays distinguish
between antibodies that recognize DBPII and those that inhibit binding to DARC receptor.
Here, the DBPII/DARC interaction was assessed by using an established cytoadherence assay
based upon multivalent interactions between DBPII on the surface of COS-7 cells and DARC
expressed in RBCs [56]. As a consequence, we and others have demonstrated a moderate cor-
relation between DBPII BIAbs and ELISA anti-DBPII antibodies (revised in [8]). Overall, our
results emphasize the relevance of examining functional aspects of the immune response, par-
ticularly in the case of immunogens such as DBPII, in which the goal of vaccination would be
to enhance broadly neutralizing antibodies targeting invasion-blocking epitopes.
To gain insights into the difference between good and poor HLA responders, we sought to
investigate whether natural HLA-DR/DQ allelic differences could be explained with respect to
binding affinity of DBPII epitopes. While predicted DBPII epitopes have a unexpected moder-
ate-to-high affinity for non-responder alleles, the binding affinity of previously described
DBPII epitopes [44–47] was much more variable, including low binding affinities of recently
described DBPII B-cells epitopes associated with strain-transcending immunity [47]. How-
ever, it seems inappropriate to extrapolate our findings to conformational B cell epitopes
because the prediction analyses used here were largely determined by the primary amino acid
sequence of the peptide-binding core. In this context, the development of tools for reliably pre-
dicting B-cell epitopes, particularly for predicting conformational epitopes, remains a major
challenge in immunoinformatics [61].
Although the predicting peptide-HLA binding affinity method used here (NetMHCIIpan—
www.cbs.dtu.dk/services/NetMHCIIpan-3.1) [62] seems to be a suitable predictive algorithm
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for T cell epitopes [28], we performed a further detailed structural in silico analysis of the
HLA-DRB1 variants. Significantly, the majority of the differences between HLA-DRB1 vari-
ants (good vs. poor responders) were located within the peptide-binding domain, leading to
significant changes in the nature of the antigen-binding groove. A striking structural differ-
ence between HLA-DRB1 variants was the presence of a glutamine residue at position 99 in
the poor responder allele (DRB114:02), as compared to aspartic acid in the good responder
alleles (DRB107:01 and DRB113:01). Remarkably, mutation of the corresponding residue
has previously been shown to result in loss of the ability of HLA-DP2 to present the metal ber-
yllium to T cells, in genetically susceptible to chronic beryllium- disease [63]. Notably, this sin-
gle mutation seems to drive helper CD4 T cells in susceptible individuals to secrete Th1-type
cytokines, such as gamma-interferon, but not IL-4, leading to beryllium-induced hypersensi-
tivity and chronic beryllium-disease [64, 65]. Consequently, we speculate that the mutation
found here in the peptide-binding groove (D247 vs. Q247) is likely to change the outcome of
the CD4+T cells immune response. Accordingly, the loss of the acidic residue in the peptide
binding groove was predicted to reduce DBPII-specific peptide binding affinity (H1 and H3),
which is expected to lead to altered antigen binding and presentation profiles, and hence poor
response of carriers of the DRB114:02 variant. It strengthens the findings that DRB114:02
could be more frequently involved with a poor antibody production [55], while the
DRB113:01 allele produces a much more robust antibody response [53, 54]. Future studies are
required to determine differences in the functionalities of DBPII epitopes in the context of dif-
ferent HLA molecules.
Notwithstanding the relevance of our results, the current study has some limitations. As we
focused on the highly variable HLA class II genes it may not have been possible to discriminate
between causal alleles and variation that is due to the linkage disequilibrium (LD) between
alleles. In fact, in most association studies it has been difficult to pinpoint the causal variants
within this genetic complex due to strong LD, population heterogeneity, and the high density
of immune-related genes [66]. Such studies have proven most successful for diseases with one
prominent predisposing genetic factor mapping to either the class I or class II region [67]. In
addition, the associations described in the present study are most likely multifactorial, and
depend on several additional factors related to the parasite and host environment. Although
the structural analysis of DRB1 variants described here suggested that specific alleles might
influence anti-DBPII antibody responses, these results indicate a first step towards the under-
standing of DBPII immune response in the context of different HLA class-II variants. We are
confident that future cellular assays can be pursued to confirm and identify mechanisms asso-
ciated with good and poor antibody responders. Finally, knowledge of the relative binding
affinities of DBPII peptides for class II molecules associated with good and poor responses to
this major P. vivax blood-stage vaccine candidate might lead to strategies for controlling the
type of helper T cells activated in response to DBPII.
Supporting Information
S1 Fig. Alleles frequencies of HLA class II (DRB1, DQA1 and DQB1 loci) of the study popu-
lation (n = 336), Amazonas state, Brazil. Most frequent alleles of HLA class II (A) DRB1; (B)
DQA1; and (C) DQB1. Allele frequencies greater than or equal to 0.01 were included in the fig-
ure. For each locus, lowercase letters (a-g) indicate statistically significant differences between
allele groups (p<0.05, Z-test).
(TIF)
S2 Fig. Binding prediction of P. vivaxDBP peptides to MHC class II molecules. Binding
affinity is depicted for the whole molecule (A) and for the Duffy Binding-Like domain (region
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II). (B) Binding affinity is given as the log of the IC50 value (nM) for good (blue line) and poor
(black line) DBPII responders. The predictions for good responders represent the average of
IC50 values of the DRB107:01 and DRB113:01 alleles; values for poor responders refer to the
prediction for the DRB114:02 allele. The horizontal lines indicate the threshold for defining
strong (<1.7) and weak binders (from 1.7 to 2.7) based on predicted affinity. Predicted values
of IC50 were specified in a sliding window of 15 amino acids in length. Previously identified
epitopes in region II of PvDBP were indicated [44–47]. Boundaries of regions I-VI of the pro-
tein were defined as previously described [68]. The three subdomains (SD) in the region are
indicated by colored bars: SD1 (green), SD2 (blue) and SD3 (orange) [69].
(TIF)
S3 Fig. Differences in peptide binding groove between HLA class II variants. The
DRB114:02 allele is depicted in yellow, DRB107:01 in green (A) and DRB113:01 in blue (B).
The peptide is shown as a cartoon in yellow. Residues within 5 Å of peptide for the three vari-
ants are shown as sticks. Residues in pink differ between variants.
(TIF)
S4 Fig. DBPII surface electrostatics. This figure presents a representation of the DBPII elec-
trostatic surface potential.
(TIF)
S1 Table. Association between antibody responses against P. vivaxDuffy binding protein
(DBPII) and HLA class II (DRB1, DQA1, and DQB1) alleles of individuals naturally
exposed to malaria.
(PDF)
S2 Table. Association between the long-term Duffy binding protein (DBPII) antibody
response and HLA class II (DRB1, DQB1 and DQA1) alleles of individuals naturally
exposed to malaria.
(PDF)
S3 Table. Association between binding inhibitory antibody (BIAbs) response against P.
vivaxDuffy binding HLA class II (DRB1, DQB1 and DQA1) exposed to malaria.
(PDF)
S1 File. Data file of HLA class II and antibody immune response.
(XLSX)
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